Evolus (EOLS) Cash & Current Investments (2018 - 2026)
Evolus (EOLS) reported Cash & Current Investments of $49.8 million for Q1 2026, down 26.66% on a YoY basis from $67.9 million in Q1 2025, and down 7.49% quarter-over-quarter from $53.8 million in Q4 2025.
Evolus (EOLS) Cash & Current Investments (2018 - 2026) Analysis & Trends
Evolus has reported Cash & Current Investments for 9 years, with the latest figure at $49.8 million in Q1 2026.
- For the quarter ending Q1 2026, Cash & Current Investments fell 26.66% year-over-year to $49.8 million; the trailing twelve-month figure through Mar 2026 stood at $49.8 million (down 26.66% YoY), and the FY2025 full-year result was $53.8 million, down 38.1% from the prior year.
- Cash & Current Investments for Q1 2026 stood at $49.8 million, down from $53.8 million in the prior quarter.
- The five-year high for Cash & Current Investments was $106.7 million in Q1 2022, with the low at $31.5 million in Q1 2023.
- Historically, Cash & Current Investments has averaged $66.2 million across 5 years, with a median of $62.8 million in 2023.
- Annual changes were most pronounced in 2022 — Cash & Current Investments jumped 381.13% — and 2023, when it plunged 70.5%.
- Evolus' Cash & Current Investments stood at $53.9 million in 2022, then advanced by 16.53% to $62.8 million in 2023, then surged by 38.37% to $87.0 million in 2024, then plunged by 38.1% to $53.8 million in 2025, then retreated by 7.49% to $49.8 million in 2026.
- The last three Cash & Current Investments figures came in at $49.8 million (Q1 2026), $53.8 million (Q4 2025), and $43.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 3.74 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 1.94 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 2.15 Bn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 77.77 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 1.32 Bn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 428.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 511.86 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 750.88 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 498.58 Mn |
| 10 | Evolus | 437.40 Mn | 387.61 Mn | 48.90 Mn | 49.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 49.79 Mn |
| Dec 31, 2025 | 53.83 Mn |
| Sep 30, 2025 | 43.52 Mn |
| Jun 30, 2025 | 61.74 Mn |
| Mar 31, 2025 | 67.89 Mn |
| Dec 31, 2024 | 86.95 Mn |
| Sep 30, 2024 | 85.04 Mn |
| Jun 30, 2024 | 93.67 Mn |
| Mar 31, 2024 | 96.96 Mn |
| Dec 31, 2023 | 62.84 Mn |
| Sep 30, 2023 | 38.69 Mn |
| Jun 30, 2023 | 41.71 Mn |
| Mar 31, 2023 | 31.46 Mn |
| Dec 31, 2022 | 53.92 Mn |
| Sep 30, 2022 | 65.57 Mn |
| Jun 30, 2022 | 84.48 Mn |
| Mar 31, 2022 | 106.67 Mn |
| Dec 31, 2021 | 146.26 Mn |
| Sep 30, 2021 | 107.80 Mn |
| Jun 30, 2021 | 131.74 Mn |